MX2014000870A - Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina. - Google Patents

Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina.

Info

Publication number
MX2014000870A
MX2014000870A MX2014000870A MX2014000870A MX2014000870A MX 2014000870 A MX2014000870 A MX 2014000870A MX 2014000870 A MX2014000870 A MX 2014000870A MX 2014000870 A MX2014000870 A MX 2014000870A MX 2014000870 A MX2014000870 A MX 2014000870A
Authority
MX
Mexico
Prior art keywords
imidazolidin
benzimidazol
ylidene
bromo
amine
Prior art date
Application number
MX2014000870A
Other languages
English (en)
Spanish (es)
Inventor
John E Donello
Mohammed I Dibas
Daniel W Gil
James A Burke
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2014000870A publication Critical patent/MX2014000870A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2014000870A 2011-07-22 2012-07-22 Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina. MX2014000870A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161510743P 2011-07-22 2011-07-22
US201161510536P 2011-07-22 2011-07-22
PCT/US2012/047777 WO2013016252A1 (en) 2011-07-22 2012-07-22 Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases

Publications (1)

Publication Number Publication Date
MX2014000870A true MX2014000870A (es) 2014-06-23

Family

ID=46599017

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000870A MX2014000870A (es) 2011-07-22 2012-07-22 Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina.

Country Status (12)

Country Link
US (1) US20130046003A1 (cg-RX-API-DMAC10.html)
EP (1) EP2734202A1 (cg-RX-API-DMAC10.html)
JP (1) JP2014521648A (cg-RX-API-DMAC10.html)
KR (1) KR20140097106A (cg-RX-API-DMAC10.html)
CN (1) CN103826631A (cg-RX-API-DMAC10.html)
AU (1) AU2012287062A1 (cg-RX-API-DMAC10.html)
BR (1) BR112014001538A2 (cg-RX-API-DMAC10.html)
CA (1) CA2842756A1 (cg-RX-API-DMAC10.html)
IL (1) IL230582A0 (cg-RX-API-DMAC10.html)
MX (1) MX2014000870A (cg-RX-API-DMAC10.html)
RU (1) RU2014106328A (cg-RX-API-DMAC10.html)
WO (1) WO2013016252A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752593B2 (en) 2018-12-28 2020-08-25 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases
US10807973B2 (en) 2018-12-28 2020-10-20 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases
AU2020454040B2 (en) 2020-06-19 2025-03-06 Endogena Therapeutics, Inc. New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU704972B2 (en) 1994-08-04 1999-05-13 H. Lundbeck A/S Novel benzimidazole derivatives
US6066675A (en) 1996-09-13 2000-05-23 The Regents Of The University Of California Method for treatment of retinal diseases
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
US20010049369A1 (en) * 2000-02-10 2001-12-06 Jablonski Monica M. Brimonidine compositions and methods for retinal degeneration
WO2002058730A2 (en) * 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20100028266A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development. Inc. Composition and methods for treating allergic response
MX2012008516A (es) * 2010-01-21 2012-10-15 Allergan Inc Agonista alfa-2 adrenergico que tiene larga duracion de efecto de baja presion intraocular.

Also Published As

Publication number Publication date
EP2734202A1 (en) 2014-05-28
JP2014521648A (ja) 2014-08-28
CA2842756A1 (en) 2013-01-31
IL230582A0 (en) 2014-03-31
CN103826631A (zh) 2014-05-28
BR112014001538A2 (pt) 2017-02-14
RU2014106328A (ru) 2015-08-27
US20130046003A1 (en) 2013-02-21
WO2013016252A1 (en) 2013-01-31
AU2012287062A1 (en) 2014-02-27
KR20140097106A (ko) 2014-08-06

Similar Documents

Publication Publication Date Title
MD4539B1 (ro) 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1
MX370543B (es) Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.
IN2014DN03206A (cg-RX-API-DMAC10.html)
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MX369385B (es) Productos para cicatrizar heridas tisulares.
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
WO2012116176A3 (en) Asymmetric ureas and medical uses thereof
PH12014500386A1 (en) Combination treatment for hepatitis c
PH12012500622A1 (en) Compounds for the treatment of dyslipidemia and related diseases
MX2013012588A (es) Inhibidores de cinasa.
WO2013085849A3 (en) Sulfate esters of noribogaine
MY168763A (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
EA201390984A1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
IN2014DN06869A (cg-RX-API-DMAC10.html)
EA201290603A1 (ru) Способ лечения
TN2013000533A1 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
MD4780B1 (ro) Urei asimetrice p-substituite şi utilizările medicale ale acestora
IN2013DN02555A (cg-RX-API-DMAC10.html)
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
WO2011113000A8 (en) Novel ester containing compositions and methods
WO2013181217A3 (en) Novel compounds and compositions for treatment of breathing control disorders or diseases
MX336278B (es) Composiciones y metodos para la prevencion y el tratamiento de heridas.
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Legal Events

Date Code Title Description
FA Abandonment or withdrawal